Cie F Foncier 06/55 Mtn News - OF3C

Reunion Neuroscience Inc. Announces Upcoming Presentations at the Anxiety and Depression Association of America (ADAA) 2024 Conference

MORRISTOWN, N.J., April 03, 2024 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc., a venture backed...

Reunion Neuroscience Abstract Accepted for Poster Presentation at 2023 ASCP Annual Meeting

TORONTO, March 27, 2023 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (NASDAQ: REUN, TSX: REUN) (“Reunion” or...

Reunion Neuroscience Files Lawsuit Against Mindset Pharma

TORONTO, March 13, 2023 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (NASDAQ: REUN, TSX: REUN) (“Reunion” or...

Reunion Neuroscience to Participate in the Oppenheimer Annual Healthcare Conference

TORONTO, March 07, 2023 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (NASDAQ: REUN, TSX: REUN) (“Reunion” or...

Reunion Neuroscience Provides Business Update and Reports Fiscal Third Quarter 2023 Financial Results

Company Completed Phase 1 Interim Data Analysis for Lead Asset, RE104, Which Showed Strong Safety and...

Reunion Neuroscience Schedules Fiscal Third Quarter 2023 Conference Call for Tuesday, February 14, 2023, at 8:30 A.M. ET

TORONTO, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (NASDAQ: REUN, TSX: REUN) (“Reunion” or...

Reunion Neuroscience Appoints Robert Alexander as Chief Medical Officer

TORONTO, Jan. 18, 2023 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (NASDAQ: REUN, TSX: REUN) (“Reunion” or...

Reunion Neuroscience Inc. Completes Interim Data Analysis for Phase 1 Clinical Trial with Novel Serotonergic Psychedelic RE104

TORONTO, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (NASDAQ: REUN, TSX: REUN) (“Reunion” or...

Reunion Neuroscience Inc. Provides 2023 Corporate Update

Company Plans to Report Phase 1 Interim Analysis for RE104 in Q1 2023 and Include Data Differentiating its...

KCSA Mental Health Virtual Investor Conference: Presentations Now Available for Online Viewing

NEW YORK, Dec. 16, 2022 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor...

KCSA Mental Health Virtual Investor Conference Agenda Announced for December 15th

NEW YORK, Dec. 13, 2022 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor...

Reunion Neuroscience Inc. to Participate in Upcoming Investor Conferences in December

TORONTO, Dec. 06, 2022 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (NASDAQ: REUN, TSX: REUN), a...

Reunion Neuroscience Puts in Place At-The-Market Equity Facility

TORONTO, Nov. 18, 2022 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (TSX: REUN, NASDAQ: REUN) ("Reunion" or...

Analysts Offer Insights on Healthcare Companies: BELLUS Health (BLU), Reunion Neuroscience (REUN) and Mainz Biomed B.V. (MYNZ)

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on BELLUS Health (BLU – Research Report), Reunion...

Reunion Neuroscience Inc. Provides Business Update and Reports Fiscal Second Quarter 2023 Financial Results

Completed RE104 Phase 1 prespecified dose cohorts and on track to deliver interim Phase 1 analysis in the first...

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Cie F Foncier 06/55 Mtn (OF3C)

Professional-Grade Tools, for Individual Investors.

OF3C News

Reunion Neuroscience Inc. Announces Upcoming Presentations at the Anxiety and Depression Association of America (ADAA) 2024 Conference

Reunion Neuroscience Abstract Accepted for Poster Presentation at 2023 ASCP Annual Meeting

Reunion Neuroscience Files Lawsuit Against Mindset Pharma

Reunion Neuroscience to Participate in the Oppenheimer Annual Healthcare Conference

Reunion Neuroscience Provides Business Update and Reports Fiscal Third Quarter 2023 Financial Results

Reunion Neuroscience Schedules Fiscal Third Quarter 2023 Conference Call for Tuesday, February 14, 2023, at 8:30 A.M. ET

Reunion Neuroscience Appoints Robert Alexander as Chief Medical Officer

Reunion Neuroscience Inc. Completes Interim Data Analysis for Phase 1 Clinical Trial with Novel Serotonergic Psychedelic RE104

Reunion Neuroscience Inc. Provides 2023 Corporate Update

KCSA Mental Health Virtual Investor Conference: Presentations Now Available for Online Viewing

KCSA Mental Health Virtual Investor Conference Agenda Announced for December 15th

Reunion Neuroscience Inc. to Participate in Upcoming Investor Conferences in December

Reunion Neuroscience Puts in Place At-The-Market Equity Facility

Analysts Offer Insights on Healthcare Companies: BELLUS Health (BLU), Reunion Neuroscience (REUN) and Mainz Biomed B.V. (MYNZ)

Reunion Neuroscience Inc. Provides Business Update and Reports Fiscal Second Quarter 2023 Financial Results

OF3C Discussion

Your Recent History

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Cie F Foncier 06/55 Mtn (OF3C) News

Cie F Foncier 06/55 Mtn (OF3C)

Professional-Grade Tools, for Individual Investors.

OF3C News

Reunion Neuroscience Inc. Announces Upcoming Presentations at the Anxiety and Depression Association of America (ADAA) 2024 Conference

Reunion Neuroscience Abstract Accepted for Poster Presentation at 2023 ASCP Annual Meeting

Reunion Neuroscience Files Lawsuit Against Mindset Pharma

Reunion Neuroscience to Participate in the Oppenheimer Annual Healthcare Conference

Reunion Neuroscience Provides Business Update and Reports Fiscal Third Quarter 2023 Financial Results

Reunion Neuroscience Schedules Fiscal Third Quarter 2023 Conference Call for Tuesday, February 14, 2023, at 8:30 A.M. ET

Reunion Neuroscience Appoints Robert Alexander as Chief Medical Officer

Reunion Neuroscience Inc. Completes Interim Data Analysis for Phase 1 Clinical Trial with Novel Serotonergic Psychedelic RE104

Reunion Neuroscience Inc. Provides 2023 Corporate Update

KCSA Mental Health Virtual Investor Conference: Presentations Now Available for Online Viewing

KCSA Mental Health Virtual Investor Conference Agenda Announced for December 15th

Reunion Neuroscience Inc. to Participate in Upcoming Investor Conferences in December

Reunion Neuroscience Puts in Place At-The-Market Equity Facility

Analysts Offer Insights on Healthcare Companies: BELLUS Health (BLU), Reunion Neuroscience (REUN) and Mainz Biomed B.V. (MYNZ)

Reunion Neuroscience Inc. Provides Business Update and Reports Fiscal Second Quarter 2023 Financial Results

OF3C Discussion

Your Recent History